July 2 (Reuters) - Vyne Therapeutics Inc VYNE.O:
VYNE THERAPEUTICS PROVIDES PROGRAM UPDATE ON ORAL BET INHIBITOR VYN202
VYNE THERAPEUTICS INC - FDA LIFTS CLINICAL HOLD FOR FEMALE PATIENTS ON 0.25 MG AND 0.5 MG DOSES
VYNE THERAPEUTICS INC - 12-WEEK TOXICOLOGY STUDY IN DOGS REQUIRED TO RESUME TRIAL IN MALES
VYNE THERAPEUTICS INC - TO STOP ENROLLING PATIENTS IN PHASE 1B PSORIASIS STUDY
VYNE THERAPEUTICS INC - UNBLINDS CLINICAL DATA FROM ENROLLED SUBJECTS IN STUDY
Source text: ID:nGNX4z5k55
Further company coverage: VYNE.O
((Reuters.Briefs@thomsonreuters.com;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。